
Xolamid T OSD1%+0.5%
Opsonin Pharma Ltd.
Brinzolamide + Timolol ophthalmic suspension is a fixed-dose combination indicated for the following: Established/FDA-approved use Reduction of elevated intraocular pressure (IOP) in patients with…
Brinzolamide + Timolol ophthalmic suspension is a fixed-dose combination indicated for the following:
Brinzolamide + Timolol is not intended as first-line, single-agent therapy; it is used specifically as combination treatment when IOP control with one class of agent alone is inadequate.
One drop of Brinzolamide + Timolol in the affected eye(s) twice daily (approximately 12 hours apart).
No dose adjustment is established for hepatic impairment. Brinzolamide + Timolol has not been specifically studied in patients with severe renal impairment; brinzolamide should be used with caution in this group (see Precautions and Warnings).
The most commonly reported side effects of Brinzolamide + Timolol include:
Less common but clinically important effects (related mainly to systemic absorption of the timolol component) include bradycardia, hypotension, fatigue, headache, and (rarely) bronchospasm in susceptible individuals. Seek medical advice if any side effect is severe or persistent.
Brinzolamide + Timolol is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.